If you have registered for this conference, please click this link to login and join. Your login details should have been sent to you by portal@smi-online.co.uk
SAE Media Group’s 5th Annual Conference
3D Cell Culture
February 09-10, 2022 | Virtual Conference
-------------------------------------------------------------------------
3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with the global 3D Cell Culture market predicted to reach a value of $3.2 Billion by 2027, researchers globally are realising the growing potential of in vitro applications for drug discovery, predictivity and validation, safety and toxicity. 3D Cell Culture technology promises to offer increased translatability in models and reduce the costly rates of drug attrition in the discovery process -- heralding the next major advance in the discovery of pharmaceuticals.
A 3D cell culture is an artificially created environment in which biological cells are permitted to grow or interact with their surroundings in all three dimensions. Unlike 2D environments (e.g., a Petri dish), a 3D cell culture allows cells in vitro to grow in all directions, similar to how they would in vivo. The crux of 3D cell culture is mimicry – how to best replicate the living environment under experimental conditions, to have the best predictive capabilities when testing drugs.
These spatial and physical aspects in 3D cultures affect the signal transduction from the outside to the inside of cells, and ultimately influence gene expression and cellular behaviour – these are especially important factors to consider when testing a new drug.
FEATURED SPEAKERS
Scientific Director, Novel Human Genetics, GSK
I started my career at Guy’s Hospital Medical School, before transitioning to industry. I have worked for GSK and its legacy companies for over thirty years. Immunology has been a common theme throughout my career, working on aspects of both innate and adaptive immunity in respiratory and autoimmune diseases. In April 2019, I joined the Novel Human Genetics Research Unit with a focus on using genetics to guide target selection for drug discovery. With the aim of reducing attrition in drug discovery, I have a long standing interest in developing and accessing better human translational models for target validation, lead discovery and candidate selection, including safety assessment and PK/PD profiling.
Workshop agenda
Opening remarks and introductions
Wendy Rowan, Scientific Director, Novel Human Genetics, GSK
I started my career at Guy’s Hospital Medical School, before transitioning to industry. I have worked for GSK and its legacy companies for over thirty years. Immunology has been a common theme throughout my career, working on aspects of both innate and adaptive immunity in respiratory and autoimmune diseases. In April 2019, I joined the Novel Human Genetics Research Unit with a focus on using genetics to guide target selection for drug discovery. With the aim of reducing attrition in drug discovery, I have a long standing interest in developing and accessing better human translational models for target validation, lead discovery and candidate selection, including safety assessment and PK/PD profiling.
The challenge in drug discovery to reduce clinical attrition
Wendy Rowan, Scientific Director, Novel Human Genetics, GSK
I started my career at Guy’s Hospital Medical School, before transitioning to industry. I have worked for GSK and its legacy companies for over thirty years. Immunology has been a common theme throughout my career, working on aspects of both innate and adaptive immunity in respiratory and autoimmune diseases. In April 2019, I joined the Novel Human Genetics Research Unit with a focus on using genetics to guide target selection for drug discovery. With the aim of reducing attrition in drug discovery, I have a long standing interest in developing and accessing better human translational models for target validation, lead discovery and candidate selection, including safety assessment and PK/PD profiling.
Assessing novel techniques in quantitative systems pharmacology to improve translatability
Enabling the better prediction of drug efficacy, toxicity, and DMPK
Applying 3D cell techniques to minimise costly late-stage clinical trial failures
The new generation of human translational models for use in drug discovery
Wendy Rowan, Scientific Director, Novel Human Genetics, GSK
I started my career at Guy’s Hospital Medical School, before transitioning to industry. I have worked for GSK and its legacy companies for over thirty years. Immunology has been a common theme throughout my career, working on aspects of both innate and adaptive immunity in respiratory and autoimmune diseases. In April 2019, I joined the Novel Human Genetics Research Unit with a focus on using genetics to guide target selection for drug discovery. With the aim of reducing attrition in drug discovery, I have a long standing interest in developing and accessing better human translational models for target validation, lead discovery and candidate selection, including safety assessment and PK/PD profiling.
Assessing the limited physiological relevance of 2D cultures
Mimicking the natural microenvironments and architectures of functioning tissues
Outlining the advantages in 3D culturing for the detection of drug-induced toxicity
The application and challenges in application of human translational models for drug discovery
Wendy Rowan, Scientific Director, Novel Human Genetics, GSK
I started my career at Guy’s Hospital Medical School, before transitioning to industry. I have worked for GSK and its legacy companies for over thirty years. Immunology has been a common theme throughout my career, working on aspects of both innate and adaptive immunity in respiratory and autoimmune diseases. In April 2019, I joined the Novel Human Genetics Research Unit with a focus on using genetics to guide target selection for drug discovery. With the aim of reducing attrition in drug discovery, I have a long standing interest in developing and accessing better human translational models for target validation, lead discovery and candidate selection, including safety assessment and PK/PD profiling.
Why the Pharmaceutical Industry has stalled on the uptake of modern translational models
Identifying the hurdles facing 3D Cell technologies: Overcoming scalability and reproducibility challenges
Wendy Rowan, Scientific Director, Novel Human Genetics, GSK
I started my career at Guy’s Hospital Medical School, before transitioning to industry. I have worked for GSK and its legacy companies for over thirty years. Immunology has been a common theme throughout my career, working on aspects of both innate and adaptive immunity in respiratory and autoimmune diseases. In April 2019, I joined the Novel Human Genetics Research Unit with a focus on using genetics to guide target selection for drug discovery. With the aim of reducing attrition in drug discovery, I have a long standing interest in developing and accessing better human translational models for target validation, lead discovery and candidate selection, including safety assessment and PK/PD profiling.
Evaluating the increased opportunities available through the production of higher-quality preclinical physiological data
Wendy Rowan, Scientific Director, Novel Human Genetics, GSK
I started my career at Guy’s Hospital Medical School, before transitioning to industry. I have worked for GSK and its legacy companies for over thirty years. Immunology has been a common theme throughout my career, working on aspects of both innate and adaptive immunity in respiratory and autoimmune diseases. In April 2019, I joined the Novel Human Genetics Research Unit with a focus on using genetics to guide target selection for drug discovery. With the aim of reducing attrition in drug discovery, I have a long standing interest in developing and accessing better human translational models for target validation, lead discovery and candidate selection, including safety assessment and PK/PD profiling.
Scientific Director, Novel Human Genetics
GSK
Scientific Director, Novel Human Genetics, GSK
I started my career at Guy’s Hospital Medical School, before transitioning to industry. I have worked for GSK and its legacy companies for over thirty years. Immunology has been a common theme throughout my career, working on aspects of both innate and adaptive immunity in respiratory and autoimmune diseases. In April 2019, I joined the Novel Human Genetics Research Unit with a focus on using genetics to guide target selection for drug discovery. With the aim of reducing attrition in drug discovery, I have a long standing interest in developing and accessing better human translational models for target validation, lead discovery and candidate selection, including safety assessment and PK/PD profiling.
VENUE
Online Virtual Event
Online Virtual Event , Online Virtual Event , United Kingdom
A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing SMi Group Trading As SAE Media Group. SMi Group Trading As SAE Media Group books all hotel rooms directly. If you are approached by a third-party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third-party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM
copyright ©
2025
SAE Media Group
